Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183972
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Resum
Background: In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) vs pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination therapy group, although a significant effect was not observed in a post-hoc analysis of all-cause hospitalization. Methods: The effect of initial combination therapy with ambrisentan and tadalafil in AMBITION was further explored to study PAH-related hospitalization, which was not reported in the primary publication. Results: Initial combination therapy was associated with a 63% reduction in risk of PAH-related hospitalization when compared with pooled monotherapy (hazard ratio [HR] 0.372, 95% confidence interval [CI] 0.217 to 0.639, p = 0.0002). For every 9 patients treated with combination therapy vs monotherapy, 1 PAH-related hospitalization could be prevented over a 1-year period. Serious adverse events leading to hospitalization, not necessarily PAH-related, occurred in 87 of 253 (34%) and 89 of 247 (36%) of patients on combination therapy and pooled monotherapy, respectively (post-hoc summary). Conclusions: Initial combination therapy with ambrisentan and tadalafil was found to reduce the risk of PAH-related hospitalization by 63% compared with pooled monotherapy.
Descripció
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
VACHIÉRY, Jean-luc, GALIÈ, Nazzareno, BARBERÀ I MIR, Joan albert, FROST, Adaani e., GHOFRANI, Hossein-ardeschir, HOEPER, Marius m, MCLAUGHLIN, Vallerie v., PEACOCK, Andrew j., SIMONNEAU, Gérald, BLAIR, Christiana, MILLER, Karen l., LANGLEY, Jonathan, RUBIN, Lewis j.. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. _Journal of Heart and Lung Transplantation_. 2019. Vol. 38, núm. 2, pàgs. 194-202. [consulta: 7 de desembre de 2025]. ISSN: 1053-2498. [Disponible a: https://hdl.handle.net/2445/183972]